Axsome Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€426.50M - Cost of goods sold
€36.35M - Gross profit
€390.15M - SG&A expenses
€396.23M - R&D expenses
€167.97M - EBITDA
-€193.68M - D&A
€7.75M - EBIT
-€197.24M - Interest expenses
€4.02M - EBT
-€213.47M - Tax expenses
-€753.86K - Net income
-€212.72M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€26.20M - Changes in working capital
-€2.82M - Operating cash flow
-€103.93M - Capex
-€103.39K - Other investing cash flow
-€509.18K - Net investing cash flow
-€405.79K - Total cash dividends paid
€0.00 - Issuance of common stock
€70.48M - Debt repayment
-€552.25K - Other financing cash flow
€40.90M - Net financing cash flow
€93.44M - Foreign exchange effects
€0.00 - Net change in cash
-€10.89M - Cash at end of period
€261.06M - Free cash flow
-€104.03M
Balance sheet
- Cash and cash equivalents
€261.06M - Cash and short-term investments
€261.06M - Total receivables
€171.30M - Inventory
€15.89M - Other current assets
€14.08M - Total current assets
€462.32M - Property, plant & equipment
€19.36M - Goodwill
€10.37M - Intangible assets
€37.68M - Long-term investments
€0.00 - Other non-current assets
€21.47M - Total non-current assets
€88.88M - Total assets
€551.21M - Accounts payable
€78.94M - Short-term debt
€60.60M - Other current liabilities
€155.19M - Total current liabilities
€294.74M - Long-term debt
€124.89M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€68.63M - Total non-current liabilities
€193.51M - Total liabilities
€488.25M - Common stock
€4.31K - Retained earnings
-€1.06B - Other equity
€0.00 - Total equity
€62.96M - Total liabilities and shareholders' equity
€551.21M
Company information
- Market capitalization
€4.34B - Employees
712 - Enterprise Value
€5.23B
Company ratios
- Gross margin
-
91.5% Much better than peer group: -272,066.4% - EBITDA margin
-
-45.4% Much better than peer group: -7,848.2% - EBIT margin
-
-46.2% Much better than peer group: -8,144.6% - EBT margin
-
-50.1% Much better than peer group: -15,337.8% - Net margin
-
-49.9% Much better than peer group: -7,855.2% - ROE
-
-337.9% Much worse than peer group: -34.1% - ROA
-
-38.6% Much better than peer group: -69.6% - Asset turnover
-
77.4% Much better than peer group: 21.4% - FCF margin
-
-24.3% Much better than peer group: -6,303.6% - FCF yield
-2.4% - Efficiency ratio
145.4% - Net sales per employee
-
€599.01K - Net income per employee
-
-€298.76K